Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018 Jul 24, 2018 7:05am EDT
Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806 Jul 10, 2018 7:00am EDT
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day Jul 09, 2018 7:00am EDT
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers Jun 29, 2018 7:00am EDT
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association Jun 15, 2018 8:00am EDT
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China Jun 14, 2018 7:05am EDT
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 Jun 04, 2018 7:04am EDT
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC May 31, 2018 7:04am EDT
